Corporate Headquarters: 480 University Avenue, Suite 1300 Toronto, Ontario, Canada, M5G 1V2
Boston Office: 1 Canal Park, Suite 100 Cambridge, MA 02141, USA
Project Saturn
Our First Platform Milestone
Our's is the world's first drug design system built around a molecular biology AI. In Project Saturn, we're using our platform to evaluate over 69 billion oligonucleotide molecules against 1 million targets, in silico, to generate a library of 1000 compounds that are experimentally verified to manipulate cell biology as intended. Think of it as a toolkit for controlling cell biology along crucial pathways, rapidly unlocking therapies with greater potential.
Saturn Tech Specs
- Anticipates the universe of molecular effects achievable by antisense oligonucleotide compounds (ASOs) in reference human cells.
- Automatically identifies all ASOs that achieve a particular change, tailored to individual genotype and leveraging up to six biological mechanisms, and counting.
- Analyses over 100,000 standard RNA isoforms for altered expression, plus thousands of novel and anticipated isoforms.
- Evaluates over 69 billion ASOs against 1 million target sites in silico.
- AI components continuously improve in a closed loop, learning from both successes and failures.
- Back-of-envelope calculation of entire ASO design space: 10^50 compounds, or, mathematically, sqrt(googol).
© 2024 DEEP GENOMICS. ALL RIGHTS RESERVED. PRIVACY POLICY